BioCentury
ARTICLE | Financial News

Kite, Juno both rise after ZUMA-1 readout

September 27, 2016 7:00 AM UTC

Cell therapy developers Kite Pharma Inc. (NASDAQ:KITE) and Juno Therapeutics Inc. (NASDAQ:JUNO) each posted gains on Tuesday after Kite reported interim data from the Phase I/II ZUMA-1 trial of KTE-C19 to treat multiple forms of lymphoma. The readout, which included response rates, came after market hours on Monday (see BioCentury Extra, Sept. 26).

Kite added $5.06 to $60.04, boosting its market cap by about $250 million to close at nearly $3 billion. Juno gained $3.77 (13%) to $33.42, adding almost $400 million in market cap to surpass $3.5 billion. ...